Immunitybio Inc - Asset Resilience Ratio
Immunitybio Inc (IBRX) has an Asset Resilience Ratio of 38.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Immunitybio Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Immunitybio Inc's Asset Resilience Ratio has changed over time. See Immunitybio Inc net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Immunitybio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IBRX stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $197.57 Million | 38.07% |
| Total Liquid Assets | $197.57 Million | 38.07% |
Asset Resilience Insights
- Very High Liquidity: Immunitybio Inc maintains exceptional liquid asset reserves at 38.07% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Immunitybio Inc Industry Peers by Asset Resilience Ratio
Compare Immunitybio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Immunitybio Inc (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Immunitybio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.67% | $6.38 Million | $382.93 Million | +1.47pp |
| 2023-12-31 | 0.20% | $1.01 Million | $504.45 Million | -0.50pp |
| 2022-12-31 | 0.70% | $2.54 Million | $362.36 Million | -28.30pp |
| 2021-12-31 | 29.01% | $136.01 Million | $468.91 Million | +1.39pp |
| 2020-12-31 | 27.62% | $61.15 Million | $221.38 Million | +2.37pp |
| 2019-12-31 | 25.25% | $36.14 Million | $143.12 Million | -6.25pp |
| 2018-12-31 | 31.51% | $57.33 Million | $181.95 Million | -10.13pp |
| 2017-12-31 | 41.64% | $104.28 Million | $250.44 Million | -18.47pp |
| 2016-12-31 | 60.11% | $190.84 Million | $317.50 Million | +27.86pp |
| 2015-12-31 | 32.25% | $118.31 Million | $366.85 Million | -- |
About Immunitybio Inc
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therap… Read more